Evidence map›Paper›PMID 28272498›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2017

The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions.

Natalia I Brzozowska, Erik J de Tonnerre, Kong M Li, Xiao Suo Wang, Aurelie A Boucher, Paul D Callaghan, Michael Kuligowski, Alex Wong, Jonathon C Arnold

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Comparing the medication costs of treating patients with schizophrenia who use cannabis with those who do not.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2024
    Article
  8. Article
  9. Cannabis and cannabinoid research · 2022
    Article
  10. Article
  11. Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions.Advances in experimental medicine and biology · 2021
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Natalia I BrzozowskaThe Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia.
Erik J de TonnerreDiscipline of Pharmacology, School of Medical Science, University of Sydney, Camperdown, NSW, Australia.
Kong M LiDiscipline of Pharmacology, School of Medical Science, University of Sydney, Camperdown, NSW, Australia.
Xiao Suo WangBosch Mass Spectrometry Facility, Bosch Institute, Sydney Medical School, University of Sydney, Camperdown, NSW, Australia.
Aurelie A BoucherThe Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia.
Paul D CallaghanThe Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia.
Michael KuligowskiAustralian Microscopy and Microanalysis Research Facility, The Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia.
Alex WongDiscipline of Pharmacology, School of Medical Science, University of Sydney, Camperdown, NSW, Australia.
Jonathon C ArnoldThe Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia.
University of Sydney · AUAustralian Nuclear Science and Technology Organisation · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cannabis use increases rates of psychotic relapse and treatment failure in schizophrenia patients. Clinical studies suggest that cannabis use reduces the efficacy of antipsychotic drugs, but there has been no direct demonstration of this in a controlled study. The present study demonstrates that exposure to the principal phytocannabinoid, Δ

Indexed as

AnimalsAntipsychotic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1BrainClozapineDose-Response Relationship, DrugDronabinolGene Expression RegulationLocomotionMaleMiceMice, Inbred C57BLMice, KnockoutProtein BindingProto-Oncogene Proteins c-fosRacloprideAntipsychotic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1ClozapineDronabinolProto-Oncogene Proteins c-fosRacloprideReceptors, Dopamine D2Receptor, Serotonin, 5-HT2ARisperidoneTritium

Identifiers

PMID28272498
PMCPMC5603813
OpenAlexW2592909584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.